A Phase 1 Study of Valemetostat Tosylate in Combination With Dato-DXd in People With Lung Cancer and With T-DXd in People With Digestive Cancers

In the U.S.

Full Title

A Phase 1b, Multicenter, Open-label Study of Valemetostat Tosylate in Combination with DXd ADCs in Subjects with Solid Tumors

Purpose

Researchers are finding the best doses of valemetostat tosylate and datopotamab deruxtecan (Dato-DXd) to use in people with lung cancer. In a second part of the study, researchers are finding the best doses of valemetostat tosylate and trastuzumab deruxtecan (T-DXd) to use in people with digestive cancers.

The people with lung cancer have non-small cell lung cancer that is inoperable (not removable with surgery) or has spread. The people with digestive cancers have advanced gastric (stomach) or gastro-esophageal junction (GEJ) cancer.

Valemetostat tosylate blocks proteins called EZH1 and EZH2, which play a role in cancer growth and survival. Dato-DXd targets cancer cells with a high level of a protein called TROP2. T-DXd targets cells that make the HER2 protein, which plays a role in cancer cell growth. These medications are given intravenously (by vein).